Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

Inclusion Criteria: * Patients must have a histologic diagnosis of pancreatic adenocarcinoma * Patient must have unresectable disease * Patients must not have received prior chemotherapy except for the following circumstances; gemcitabine and capecitabine chemotherapy given in the adjuvant setting is allowed if the recurrence is greater than 6 months from the completion of chemotherapy; radiation sensitizing doses of 5-fluororuracil or capecitabine are allowed as part of adjuvant treatment and recurrence must be documented greater than 6 months from the completion of adjuvant therapy * Computed tomography (CT) or magnetic resonance imaging (MRI) scan must be obtained within 4 weeks prior to study entry * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Absolute neutrophil count \> 1,500/mcl * Platelet count \> 100,000/mcl * Creatinine \< 1.4 mg/dl and/or a measured creatinine clearance \> 60 cc/min * Bilirubin \< 1.4 mg/dl * Alanine aminotransferase (ALT), aspartate aminotransferase (AST) no greater than 3.0 times the upper limit of normal * Patients currently being treated for severe infections or who are recovering from major surgery or other intercurrent illnesses are ineligible until recovery is deemed complete by the investigator * Patients must not be pregnant or nursing; women and men of reproductive potential must have agreed to use an effective contraceptive method * All patients must be informed of the investigational nature of this study and m…